# KRAS in non-small cell lung cancer

2 EU-approved indications in non-small cell lung cancer need a KRAS result: adagrasib (2nd line, advanced) and sotorasib (2nd line, advanced).

## Approved indications

### KRAS mutation

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Adagrasib](https://oncolabels.com/drugs/adagrasib) (Krazati) | KRAS G12C | Monotherapy | 2nd line, advanced | Disease progression after at least one prior systemic therapy |
| [Sotorasib](https://oncolabels.com/drugs/sotorasib) (Lumykras) | KRAS G12C | Monotherapy | 2nd line, advanced | After at least one prior line of systemic therapy |

## Label wording

- **Adagrasib** (Krazati), Non-small cell lung cancer, 2nd line, advanced: “KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf)
- **Sotorasib** (Lumykras), Non-small cell lung cancer, 2nd line, advanced: “LUMYKRAS as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and who have progressed after at least one prior line of systemic therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/non-small-cell-lung-cancer/kras